11.08.06
Crucell N.V. and DSM Biologics have opened the Percivia PER.C6 Development Center as part of a previously announced joint venture between the two companies. Percivia was designed to advance the PER.C6 cell line and provide solutions for the production of pharmaceutical proteins to licensees utilizing the PER.C6 human cell line in the biopharma industry.
"Percivia's state-of-the-art facility will support the use of PER.C6 cells in the manufacturing of human therapeutic proteins," said Dr. Marco Cacciuttolo, chief executive officer of Percivia. "With more than 20 companies licensing the technology for protein and monoclonal antibody production, we anticipate that the PER.C6 cell line will become the leading choice for many biotechnology and pharmaceutical companies, and Percivia is well-positioned to support this growing market."
"The tremendous promise and potential of PER.C6 technology has become apparent not only from our own work, but particularly from customer and licensee feedback," commented Leendert Staal, chief executive officer of DSM Pharmaceutical Products. "This R&D center dedicated to the further development of the PER.C6 technology platform will play a key role in establishing the PER.C6 cell line as a new standard in the production of human therapeutic proteins."
Ronald H.P. Brus, president and chief executive officer of Crucell, said, "Our current and future PER.C6 technology licensees will be able to continuously benefit from the know-how generated in the Percivia PER.C6 Development Center. The recombinant protein market is very large and still growing, and we believe that this center will provide an important service to licensees in this progressive industry."
"Percivia's state-of-the-art facility will support the use of PER.C6 cells in the manufacturing of human therapeutic proteins," said Dr. Marco Cacciuttolo, chief executive officer of Percivia. "With more than 20 companies licensing the technology for protein and monoclonal antibody production, we anticipate that the PER.C6 cell line will become the leading choice for many biotechnology and pharmaceutical companies, and Percivia is well-positioned to support this growing market."
"The tremendous promise and potential of PER.C6 technology has become apparent not only from our own work, but particularly from customer and licensee feedback," commented Leendert Staal, chief executive officer of DSM Pharmaceutical Products. "This R&D center dedicated to the further development of the PER.C6 technology platform will play a key role in establishing the PER.C6 cell line as a new standard in the production of human therapeutic proteins."
Ronald H.P. Brus, president and chief executive officer of Crucell, said, "Our current and future PER.C6 technology licensees will be able to continuously benefit from the know-how generated in the Percivia PER.C6 Development Center. The recombinant protein market is very large and still growing, and we believe that this center will provide an important service to licensees in this progressive industry."